Oscar Kuipers

Oscar Kuipers is a Full Professor and Head of the Department of Molecular Genetics at the Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, the Netherlands, a position he has held since 1999. He is an internationally recognized leader in antimicrobials, bacterial cell biology, synthetic biology, and bacterial gene regulation. Kuipers also serves as founder and CSO of Omnicin Therapeutics, a company he established in 2019 to develop novel antibiotics for clinical use.

Dr. Kuipers earned his PhD in Biochemistry from Utrecht University with research on "Probing the mechanism of pancreatic phospholipase A2 by protein engineering." His early career included positions at NIZO Food Research (1990-1999), where he served as Head of Genetics from 1997-1999, and an EMBO Fellowship in Paris Orsay in 1988.

Kuipers' research focuses on several interconnected areas that have significantly advanced our understanding of bacterial systems and antimicrobial development. He is a world-leading expert on lantibiotics (modified antimicrobial peptides produced by bacteria), having unraveled the biosynthesis route of nisin and discovered that nisin induces its own expression through bacterial cell-to-cell signaling. His pioneering work on phenotypic heterogeneity at the single-cell level revealed that differentiation in bacterial cultures is omnipresent and has important implications for bacterial behavior. More recently, Kuipers has developed a synthetic biology suite to mimic non-ribosomally produced peptide antibiotics (NRPS) with ribosomally produced and posttranslationally modified peptides (RiPPs), with applications for developing novel antimicrobials for pharmaceutical use.

His publication record demonstrates consistent leadership in antimicrobial research, with particular emphasis on lantibiotics, peptide engineering, and bacterial population dynamics. The research trajectory shows an evolution from fundamental biochemical studies to applied pharmaceutical development, with recent work focusing on overcoming antibiotic resistance through innovative approaches like synthetic helper peptides and hybrid lanthipeptides.

Dr. Kuipers has received numerous prestigious honors and awards throughout his career:

• Chairman of jury to appoint new members to Royal Netherlands Academy of Arts and Sciences (KNAW) (2021)
• Royal decoration of Knight in the Order of the Dutch Lion by King Willem Alexander (2019)
• Honorary Professor at Nankai University, China (2019)
• ISI Thomson Reuters Highly Cited Researcher (2016)
• Elected Executive Board Member, European Academy of Microbiology (EAM) (2015)
• Elected Member, European Academy of Microbiology (EAM) (2013)
• iGEM Team Groningen: European and World Champion 2012 Synthetic Biology (2012)
• Elected Member, Royal Netherlands Academy of Arts and Sciences (KNAW) (2011)
• Simon Stevin Meester Award (Science and Technology Award of STW, Dutch Science Council) €500,000 (2011)

As supervisor and coordinator of the iGEM team Groningen from 2008-2015, Kuipers mentored numerous students in synthetic biology competitions. His research has been supported by significant funding, including the Simon Stevin Meester Award of €500,000. His work has resulted in an impressive publication record with an h-factor of 113 (Google Scholar) and over 50,000 citations.

Kuipers leads research at the Groningen Biomolecular Sciences and Biotechnology Institute, where his group focuses on developing novel antimicrobials for pharmaceutical applications. His recent work has centered on using lantibiotics as templates for new antibiotic development, with his synthetic biology suite enabling the creation of ribosomally produced and posttranslationally modified peptides (RiPPs) as alternatives to non-ribosomally produced peptide antibiotics (NRPS). In 2019, he translated this research into practical applications by founding Omnicin Therapeutics to develop novel antibiotics for clinical use.